You might also be interested in:

BCG's INVERTO announces new Managing Director and plans to accelerate UK growth

London (ots) - INVERTO, Boston Consulting Group's procurement focused subsidiary, is expanding its UK presence ...

THOMAS SABO inspires with paradisiacal gift ideas for Mother's Day 2019

Lauf/Pegnitz (ots) - Say thank-you for Mother's Day 2019. THOMAS SABO presents a paradisiacal variety of ...

23.01.2019 – 16:01

Philogen

Philogen Announces Collaboration

Siena, Italy (ots/PRNewswire)

Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics.

(Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg )

"We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. Duccio Neri, Philogen's CEO.

No financial details of the agreement were released.

About Philogen

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit http://www.philogen.com.

Contact:

Christian Lizak
PhD
Senior Scientist - Business Development
+41-43-544-88-05
christian.lizak@philogen.com

Original content of: Philogen, transmitted by news aktuell

All Releases
Subscribe to Philogen
  • Printable version
  • PDF version

Places in this release

Topics in this relase